Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmDJuly 8th 2025
Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.